Singer Lous and the Yakuza has revealed that she suffers from multiple sclerosis, an autoimmune disease that causes disability.
- Singer Lous and the Yakuza revealed she had multiple sclerosis on her Instagram account.
- The artist explains that this diagnosis is “a relief, even if there is no cure”.
- Multiple sclerosis is an autoimmune disease that affects the central nervous system.
“A year ago, two weeks after the release of my second album, I woke up paralyzed in both legs. I had no idea what was happening to me, and I was in a wheelchair for 3 months because I couldn’t walk anymore.
This week, singer Lous and the Yakuza revealed she had multiple sclerosis on her Instagram account.
Multiple sclerosis: this diagnosis is “a relief, even if there is no cure”
“I was lost and confused, searching for a diagnosis. There was no visible problem with my legs, so what was it?”she says. “We (my family, friends and I) went from one doctor to another to find out what was wrong. And after a few calls, I was advised to meet one of the best neurologists in Paris “, she continues.
Following an MRI of her brain and spine, the 27-year-old Belgian-Congolese star then describes the announcement of her diagnosis, accompanied by a reflection that she considers racist. “I have good news for you: you are a black woman BUT you have a brain. And I think you have multiple sclerosis,” his doctor then told him.
At the end of his post, the artist explains that this diagnosis is “a relief, even if there is no cure.”
Multiple sclerosis is an autoimmune disease
Multiple sclerosis is an autoimmune disease that affects the central nervous system. “A dysfunction of the immune system leads to lesions which cause motor, sensory, cognitive, visual or even sphincter disturbances (most often urinary and intestinal)”, explains Inserm.
In the more or less long term, these disorders can progress towards irreversible disability. And while current treatments help reduce relapses and improve patients’ quality of life, they are most often insufficiently effective in preventing the progression of disability in the medium term.
“However, particularly promising new therapeutic strategies could change the situation in the years to come,” concludes the research center.